Author(s):
Suresh P.K., Ramkar S
Email(s):
suresh.preeti@gmail.com
DOI:
10.52711/0974-360X.2024.00931 
Address:
Suresh P.K.1, Ramkar S2
1University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (C.G.) India-492010.
2Kamla Institute of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Junwani, Bhilai, Durg (C.G.)-490020.
*Corresponding Author
Published In:
Volume - 17,
Issue - 12,
Year - 2024
ABSTRACT:
Androgenic alopecia (AGA), also called male-pattern hair loss, is a hair loss condition facilitated by dihydrotestosterone (DHT), the potent form of testosterone. The hallmark of this disorder is a patterned decrease in scalp hair density. In androgenic alopecia, 5a-reductase iso-enzyme, which is responsible for conversion of testosterone to DHT, is increased in the scalp follicles. In the presence of DHT, hair cycle is shortened and progressively miniaturizes scalp follicles. Like most tissues, hair undergoes continuous turnover throughout life. Hair follicles are replaced periodically; the time interval is dependent on location and by the process of hair cycling. AGA occurs in a sequential step. In genetically predisposed men the initial development is bitemporal recession, followed by diffuse frontal loss and after there a bald patch over the vertex of the scalp accurse. Ultimately, all the hair over the crown is lost. With each new cycle, hair follicles are regenerated and follicular stem cells are responsible for this and recapitulate many of the signals of embryologic development. Various factors are influence and alter the regenerating hair follicle with advancing age. In this review, the recent advances in the understanding of molecular mechanisms of androgenic alopecia are discussed. The recent developments in the pharmacotherapy of this condition is also reviewed and presented.
Cite this article:
Suresh P.K., Ramkar S. Androgenic Alopecia: Recent Understanding of the Androgenetic Receptor-Mediated Molecular Mechanisms and Current Pharmacotherapy. Research Journal Pharmacy and Technology. 2024;17(12):6137-5. doi: 10.52711/0974-360X.2024.00931
Cite(Electronic):
Suresh P.K., Ramkar S. Androgenic Alopecia: Recent Understanding of the Androgenetic Receptor-Mediated Molecular Mechanisms and Current Pharmacotherapy. Research Journal Pharmacy and Technology. 2024;17(12):6137-5. doi: 10.52711/0974-360X.2024.00931 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-12-68
REFERENCES:
1. Mazzarella, F., Loconsole, F., Cammisa, A., Mastrolonardo, M. and Vena, G. A. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. Journal of Dermatological Treatment. 1997; 8: 189–192.
2. Sinclair, R. D. and Sinclair, R. D. Male androgenetic alopecia. (2017) doi:10.1517/14656561003752730.
3. Ceruti, J. M., Leirós, G. J. and Balañá, M. E. Androgens and androgen receptor action in skin and hair follicles. Molecular and Cellular Endocrinology. 2018; 465: 122–133.
4. Ă, S. P. et al. Therapeutic considerations related to finasteride administration in male androgenic alopecia and benign prostatic hyperplasia. 2017; 65.
5. Khan, M. Z. U. et al. Finasteride Topical Delivery Systems for Androgenetic Alopecia. Current Drug Delivery. 2018; 15: 1100–1111.
6. Ateeq Ahmad, S. S. A New Topical Formulation of Minoxidil and Finasteride Improves Hair Growth in Men with Androgenetic Alopecia. Journal of Clinical and Experimental Dermatology Research. 2015; 6: 6–11.
7. Kaufman, K. D. and Francisco, S. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, Daily. 2002: 517–523 doi:10.1067/mjd.2002.120537.
8. Esen Salman, K., Kucukunal, N. A., Kivanc Altunay, I. and Aksu Cerman, A. Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: Hospital-based cross-sectional study in Turkey. Anais Brasileiros de Dermatologia. 2017; 92: 35–40.
9. Tang, P. H., Chia, H. P., Cheong, L. L. and Koh, D. A community study of male androgenetic alopecia in Bishan, Singapore. Singapore Medical Journal. 2000; 41: 202–205.
10. Neste, D. V. A. N., Fuh, V. and Wolff, H. Finasteride increases anagen hair in men with androgenetic alopecia. 2000: 804–810.
11. Sintov, A., Serafimovich, S. and Gilhar, A. New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice. 2000; 194: 125–134.
12. Avital, Y. S., Morvay, M., Gaaland, M. and Kemny, L. Study of the international epidemiology of androgenetic alopecia in young caucasian men using photographs from the internet. Indian Journal of Dermatology. 2015; 60: 419.
13. Mirmirani, P. Maturitas Age-related hair changes in men : Mechanisms and management of alopecia and graying. Maturitas. 2015; 80: 58–62.
14. Gan, D. C. C. and Sinclair, R. D. Prevalence of male and female pattern hair loss in Maryborough. The journal of investigative dermatology. Symposium proceedings / the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research. 2005; 10: 184–189.
15. Kaliyadan, F., Nambiar, A. and Vijayaraghavan, S. Androgenetic alopecia : An update. 2013; 79.
16. Lolli, F. et al. Androgenetic alopecia : a review. Endocrine. 2017; 9–17. doi:10.1007/s12020-017-1280-y.
17. Cranwell, W., Hons, M., Hons, B. and Sinclair, R. Male Androgenetic Alopecia. 2018; 1–30.
18. Chueh, S. C. et al. Therapeutic strategy for hair regeneration: Hair cycle activation, niche environment modulation, wound-induced follicle neogenesis, and stem cell engineering. Expert Opinion on Biological Therapy. 2013; 13: 377–391.
19. Randall, V. A. Molecular Basis of Androgenetic Alopecia. Aging Hair. 2010 doi:10.1007/978-3-642-02636-2.
20. Otberg, N., Finner, A. M. and Shapiro, J. Androgenetic Alopecia. Endocrinology and Metabolism Clinics of North America. 2007; 36: 379–398.
21. Cloke, B. and Christian, M. The role of androgens and the androgen receptor in cycling endometrium. Molecular and Cellular Endocrinology. 2012; 358: 166–175.
22. Sehgal, V. N., Aggarwal, A. K., Srivastava, G. and Rajput, P. Male Pattern Androgenetic Alopecia. 2006.
23. Davis, D. S. and Callender, V. D. International Journal of Women’s Dermatology Review of quality of life studies in women with alopecia. International Journal of Women’s Dermatology. 2018; 4: 18–22.
24. Sinclair, R. D., Perera, E., Sinclair, R. and Alexander, S. Androgenetic Alopecia. 2015. doi:10.3109/9781439808078-33.
25. Lee, W. S. et al. Guidelines for management of androgenetic alopecia based on BASP classification – the Asian consensus committee guideline. 2013; 1026–1034. doi:10.1111/jdv.12034.
26. Tru, R. M. Molecular mechanisms of androgenetic alopecia. 2002; 37: 981–990.
27. Ellis, J. A., Sinclair, R. and Harrap, S. B. Androgenetic alopecia : Pathogenesis and potential for therapy Androgenetic alopecia : pathogenesis and potential for therapy. 2016 doi:10.1017/S1462399402005112.
28. Trüeb, R. M. Inflammatory Phenomena and Fibrosis in Androgenetic Alopecia Androgenetic. in 16th Annual Meeting European Hair Research Society Barcelona. 2012: 21–23.
29. Ebling, F. J. G. 8 Hair follicles and associated glands as androgen targets. Clinics in Endocrinology and Metabolism. 1986; 15: 319–339.
30. Mak, W. C. et al. Triggering of drug release of particles in hair follicles. Journal of Controlled Release. 2012; 160: 509–514.
31. Patzelt, A. and Lademann, J. Drug delivery to hair follicles. Expert Opinion on Drug Delivery. 2013; 10: 787–797.
32. Lademann, J. et al. Hair follicles - A long-term reservoir for drug delivery. Skin Pharmacology and Physiology. 2006; 19: 232–236.
33. Stenn, K. S., Prouty, S. M. and Seiberg, M. Molecules of the cycling hair follicle - a tabulated review. Journal of Dermatological Science. 1994; 7.
34. Botchkareva, N. V., Ahluwalia, G. and Shander, D. Apoptosis in the hair follicle. Journal of Investigative Dermatology. 2006; 126: 258–264.
35. Fischer, T. W. et al. Differential effects of caffeine on hair shaft elongation, matrix and outer root sheath keratinocyte proliferation, and transforming growth factor-β2/insulin-like growth factor-1-mediated regulation of the hair cycle in male and female human hair follicle. British Journal of Dermatology. 2014; 171: 1031–1043.
36. S, I., C, T. and S, I. Acceleration of Hair Growth Rate by Topical Liposomal Cepharanthine in Male Androgenetic Alopecia. Hair Therapy and Transplantation. 2016; 6: 6–7.
37. Soma, T., Ogo, M., Suzuki, J., Takahashi, T. and Hibino, T. Analysis of apoptotic cell death in human hair follicles in vivo and in vitro. Journal of Investigative Dermatology. 1998; 111: 948–954.
38. itami1990.pdf.
39. Robinson, H. N. and Martin, N. F. Topical treatment of acne WItH Cephalosporns. 1995.
40. Paus, R. and Cotsarelis, G. The biology of hair follicles. New England Journal of Medicine. 1999; 341: 491–497.
41. Wosicka, H. and Cal, K. Targeting to the hair follicles: Current status and potential. Journal of Dermatological Science. 2010; 57: 83–89.
42. Alonso, L. and Fuchs, E. The hair cycle. 2006: 391–393.
43. Ford, S. J. et al. Structural and Functional Analysis of Intact Hair Follicles and Pilosebaceous Units by Volumetric Multispectral Optoacoustic Tomography. Journal of Investigative Dermatology. 2016; 136: 753–761.
44. Amin, S. S. and Sachdeva, S. Alopecia areata: A review. Journal of the Saudi Society of Dermatology and Dermatologic Surgery. 2013; 17: 37–45.
45. Schiffer, L., Arlt, W. and Storbeck, K. H. Intracrine androgen biosynthesis, metabolism and action revisited. Molecular and Cellular Endocrinology. 2018; 465: 4–26.
46. Pretorius, E. et al. 11-Ketotestosterone and 11-ketodihydrotestosterone in castration resistant prostate cancer: Potent androgens which can no longer be ignored. PLoS ONE. 2016; 11: 1–17.
47. Storbeck, K. H. et al. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: A putative role in castration resistant prostate cancer? Molecular and Cellular Endocrinology. 2013; 377: 135–146.
48. Anuka, E., Gal, M., Stocco, D. M. and Orly, J. Expression and roles of steroidogenic acute regulatory (StAR) protein in ‘non-classical’, extra-adrenal and extra-gonadal cells and tissues. Molecular and Cellular Endocrinology. 2013; 371: 47–61.
49. Manenda, M. S., Hamel, C. J., Masselot-Joubert, L., Picard, M. È. and Shi, R. Androgen-metabolizing enzymes: A structural perspective. Journal of Steroid Biochemistry and Molecular Biology. 2016; 161: 54–72.
50. Zouboulis, C. C. et al. PNAS-2002-Zouboulis-. 2000;99: 7148-53.
51. Zouboulis, C. C. Acne and sebaceous gland function. Clinics in Dermatology. 2004; 22: 360–366.
52. Kaufman, K. D. Androgen metabolism as it affects hair growth in androgenetic alopecia. 1996; 14
53. Hoffman, R. M. The hair follicle and its stem cells as drug delivery targets. Expert Opinion on Drug Delivery. 2006; 3: 437–443.
54. Li, L. et al. Selective induction of apoptosis in the hamster flank sebaceous gland organ by a topical liposome 5-α-reductase inhibitor: A treatment strategy for acne. Journal of Dermatology. 2010; 37: 156–162.
55. Leyden, J. et al. Finasteride in the treatment of men with frontal male pattern hair loss. 1999: 930–937.
56. Janne, O. A., Palvimo, J. J., Kallio, P. and Mehto, M. Androgen Receptor and Mechanism of Androgen Action. 1993.
57. Mendonca, B. B. et al. Reprint of “Steroid 5α-reductase 2 deficiency”. Journal of Steroid Biochemistry and Molecular Biology. 2017; 165: 95–100.
58. Li, J. and Al-Azzawi, F. Mechanism of androgen receptor action. Maturitas. 2009; 63: 142–148.
59. Kelly, Y., Blanco, A. and Tosti, A. Androgenetic Alopecia: An Update of Treatment Options. Drugs. 2016; 76: 1349–1364.
60. Singal, A., Sonthalia, S. and Verma, P. Female pattern hair loss. Indian Journal of Dermatology, Venereology and Leprology. 2013; 79: 626–640.
61. Srulevich, M. Medical management of benign prostatic hypertrophy in older men. Clinical Geriatrics. 2009; 17: 28–32.
62. McElwee, K. J. and Shapiro, J. S. Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Letter. 2012; 17: 1–4.
63. Kaufman, K. D. et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1998; 39: 578–89.
64. Guo, H., Gao, W. V., Endo, H. and McElwee, K. J. Experimental and early investigational drugs for androgenetic alopecia. Expert Opinion on Investigational Drugs. 2017; 26; 917–932.
65. Yu, M. et al. Hair follicles and their role in skin health. Expert Review of Dermatology. 2006; 1: 855–871.
66. Kumar, P., Singh, S., Handa, V. and Kathuria, H. Oleic Acid Nanovesicles of Minoxidil for Enhanced Follicular Delivery. Medicines. 2018; 5: 103.
67. Usmania, Ajay Bilandi, M. K. K. Minoxidil Emulgel for Androgenic Alopecia : A Literature Review Including Patents. 2017; 5: 49–58.
68. Hatem, S. et al. Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal. European Journal of Pharmaceutical Sciences. 2018; 122.
69. Olubukola Sinbad, O., Folorunsho, A. A., Olabisi, O. L., Abimbola Ayoola, O. and Johnson Temitope, E. Vitamins as Antioxidants. Journal of Food Science and Nutrition Research. 2019; 2: 214–235.
70. Koca, R., Armutcu, F., Altinyazar, H. C. and Gürel, A. Evaluation of lipid peroxidation, oxidant/antioxidant status, and serum nitric oxide levels in alopecia areata. Medical Science Monitor. 2005; 11: 296–299.
71. Fernández, E., Martínez-Teipel, B., Armengol, R., Barba, C. and Coderch, L. Efficacy of antioxidants in human hair. Journal of Photochemistry and Photobiology B: Biology. 2012; 117: 146–156.
72. Otberg, N. et al. Follicular penetration of topically applied caffeine via a shampoo formulation. Skin Pharmacology and Physiology. 2007; 20: 195–198.
73. Ramezani, V. et al. Formulation and optimization of transfersome containing minoxidil and caffeine. Journal of Drug Delivery Science and Technology. 2018; 44: 129–135.
74. Daniels, G., Akram, S., Westgate, G. E. and Tamburic, S. Can plant-derived phytochemicals provide symptom relief for hair loss? A critical review. International Journal of Cosmetic Science. 2019; 41: 332–345.
75. Michael, J., Nadine, V., Maike, K. and Adolf, B. Erratum: Caffeine and Its Pharmacological Benefits in the Management of Androgenetic Alopecia: A Review. Skin Pharmacol Physiol. 2020; 33: 93-109 DOI: 10.1159/000508228).
76. Sonthalia, S., Daulatabad, D. and Tosti, A. Hair Restoration in Androgenetic Alopecia : Looking Beyond Minoxidil , Finasteride and Hair Transplantation. 2016; 2: 1–13.
77. Jo, S. J. et al. Topical valproic acid increases the hair count in male patients with androgenetic alopecia : A randomized , comparative , clinical feasibility study using phototrichogram analysis. Journal of Dermatology. 2014; 41: 1–7.
78. Ashique, S., Sandhu, N. K., Haque, S. N. and Koley, K. A Systemic Review on Topical Marketed Formulations , Natural Products, and Oral Supplements to Prevent Androgenic Alopecia : National Institutes of Health. Natural Products and Bioprospecting. 2020; 10: 345–365.
79. Sonthalia, S., Daulatabad, D. and Tosti, A. Journal of Cosmetology and Trichology Hair Restoration in Androgenetic Alopecia : Looking Beyond Minoxidil, Finasteride and Hair Transplantation. 2016; 2: 1–13.
80. Ito, T. et al. Roxithromycin antagonizes catagen induction in murine and human hair follicles: Implication of topical roxithromycin as hair restoration reagent. Archives of Dermatological Research. 2009; 301: 347–355.
81. Csongradi, C., du Plessis, J., Aucamp, M. E. and Gerber, M. Topical delivery of roxithromycin solid-state forms entrapped in vesicles. European Journal of Pharmaceutics and Biopharmaceutics. 2017; 114: 96–107.
82. Wosicka-fra, H. et al. Roxithromycin-loaded lipid nanoparticles for follicular targeting. 2015; 495; 807–815.
83. Shamma, R. N. and Aburahma, M. H. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. International Journal of Nanomedicine. 2014; 9: 5449–5460.
84. Kim, G. K. and Del Rosso, J. Q. Oral spironolactone in post-teenage female patients with acne vulgaris: Practical considerations for the clinician based on current data and clinical experience. Journal of Clinical and Aesthetic Dermatology. 2012; 5: 37–50.
85. Abdel-Raouf, H., Aly, U. F., Medhat, W., Ahmed, S. S. and Abdel-Aziz, R. T. A. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study. Dermatologic Therapy. 2021; 34: 0–2.
86. Lumachi, F. and Basso, S. M. M. Medical Treatment of Hirsutism in Women. Current Medicinal Chemistry. 2010; 17: 2530–2538.
87. Perez, B. S. H. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. 2004: 112–115 doi:10.1016/S0306-9877(03)00264-0.
88. Jiang, J., Tsuboi, R., Kojima, Y. and Ogawa, H. Topical Application of Ketoconazole Stimulates Hair Growth in C3H / HeN Mice. The Journal of Dermatology. 2005; 32: 243–247.
89. El-garf, A., Mohie, M. and Salah, E. Trichogenic effect of topical ketoconazole versus minoxidil 2 % in female pattern hair loss : a clinical and trichoscopic evaluation. Biomedical Dermatology. 2019; 3: 1–8.
90. Kaushik, R., Institutions, R., Gupta, D. and Institutions, R. Alopecia : Herbal remedies. International Journal of Pharmaceutical Sciences and Research. 2014; 2: 1631–1637.
91. Ramkar, S. et al. Nano-Lipidic Carriers as a Tool for Drug Targeting to the Pilosebaceous Units. CPD. 2020; 26: 3251–3268.
92. Ramkar, S. and Suresh, P. K. Finasteride-loaded nano-lipidic carriers for follicular drug delivery: preformulation screening and Box-Behnken experimental design for optimization of variables. Heliyon. 2022; 8: e10175.
93. Knorr, F. et al. Follicular transport route - Research progress and future perspectives. European Journal of Pharmaceutics and Biopharmaceutics. 2009; 71: 173–180.